Kenalog (Triamcinolone Acetonide) Steroid: Proper Usage and Dosage
Kenalog (triamcinolone acetonide) is an injectable corticosteroid available in 40 mg/mL and 80 mg/mL formulations, indicated for intramuscular or intra-articular administration only. 1
Formulations and Administration Routes
Kenalog is available as an injectable suspension in two concentrations:
- Kenalog-40: 40 mg/mL (available in 1 mL, 5 mL, and 10 mL vials)
- Kenalog-80: 80 mg/mL (available in 1 mL and 5 mL vials) 1
Administration routes are limited to:
- Intramuscular injection
- Intra-articular injection 1
Dosage Guidelines by Indication
Allergic Rhinitis
- For intranasal formulation (Nasacort Allergy 24HR):
- Ages 2-5 years: 1 spray per nostril daily
- Ages 6-11 years: 2 sprays per nostril daily
- Ages ≥12 years: 2 sprays per nostril 1-2 times daily 2
Dermatological Conditions
- For lichen sclerosus with topical steroid-resistant areas:
- Intralesional triamcinolone 10-20 mg after excluding malignancy 2
- For alopecia areata:
- Intralesional injection of triamcinolone acetonide 5-10 mg/mL into affected areas 2
Joint Conditions
- For knee osteoarthritis:
- 10 mg intra-articular injection is non-inferior to 40 mg for pain relief, with effects lasting approximately 12 weeks 3
- For trigger finger:
- 20 mg dose shows higher clinical effectiveness (79%) at 6 months compared to 10 mg (62%) or 5 mg (52%) 4
Atopic Dermatitis
- Not recommended for chronic use due to risk of rebound flares
- If used as transitional therapy in severe cases:
- Dosage range: 0.5-1.0 mg/kg
- Requires tapering schedule to prevent adrenal suppression 2
Important Precautions and Monitoring
Avoid prolonged use due to potential side effects including:
For long-term administration (if necessary):
- Monitor blood pressure
- Consider ophthalmologic examination
- Evaluate for hypothalamic-pituitary-adrenal axis suppression
- Monitor bone density in adults
- Track growth velocity in children 2
Potential Adverse Effects
Common side effects include:
- Injection site reactions
- Pharyngitis, epistaxis, and cough (with intranasal use) 2
Severe reactions may include:
Clinical Pearls
- For facial application, consider alternative agents like topical calcineurin inhibitors due to increased risk of steroid-induced atrophy 5
- For maintenance therapy, consider reducing application frequency while maintaining efficacy 5
- The unique pharmacokinetics of intramuscular triamcinolone acetonide allows for longer duration of action compared to other corticosteroids 7
- When treating trigger finger, higher doses (20 mg) provide better long-term outcomes than lower doses 4